Pregabalin Capsule
Product Images NDC 80425-0029

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 75 mg taken three or twice daily, Pregabalin 25 mg taken three times daily, and placebo. The graph shows the comparative effectiveness of different Pregabalin dosages over a range of pain improvement percentages.*

FDA Label Image

Fig 10

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR over a 180-day period comparing Pregabalin and placebo. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis shows the duration in days. The solid line indicates Pregabalin, and the dashed line represents placebo.*

FDA Label Image

Fig 11

A line graph showing the percent of subjects improved on the vertical axis and percent improved from baseline to week 12 BOCF on the horizontal axis for Pregabalin and Placebo treatment groups. The graph compares improvement rates over a range of percentages for both treatments.*

FDA Label Image

Fig 12

A line graph comparing the percent of subjects improved from baseline to week 16 between Pregabalin and placebo groups in a BOCF analysis. The x-axis shows percent improvement from greater than 0% to 100%, and the y-axis shows the percent of subjects improved from 0% to 100%. Pregabalin shows a higher percentage of subjects improved across the range compared to placebo.*

FDA Label Image

Fig 2

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, with Pregabalin showing a higher percentage of patient improvement across pain improvement levels.*

FDA Label Image

Fig 3

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day against a placebo over a measure of pain improvement. Each treatment group is represented by a distinct line trend.*

FDA Label Image

Fig 4

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph illustrates patient improvement trends at varying pain improvement percentages.*

FDA Label Image

Fig 5

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo, illustrating patient response to different treatments over a range of pain improvement percentages.*

FDA Label Image

Fig 6

A bar graph showing responder rates (%) in two clinical studies, Study E1 and Study E3, comparing placebo and different doses of Pregabalin. Study E1 presents responder rates for placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses, all administered BID, with increasing responder rates. Study E3 shows responder rates for placebo, 600 mg/day BID, and 600 mg/day TID doses. The graph includes sample sizes (N) for each group and denotes statistical significance versus placebo.*

FDA Label Image

Fig 7

A line graph depicting seizure reduction as median percent change from baseline versus dose (mg/day) for pregabalin across four studies: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. The chart includes data points with significant p-values showing increased seizure reduction at doses beyond placebo.*

FDA Label Image

Fig 9

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin at 600 mg, 450 mg, and 300 mg daily doses and placebo. Four curves show the relationship, with the 600 mg dose consistently showing higher patient improvement percentages.*

FDA Label Image

Formula

An illustrated formula for calculating creatinine clearance (CLCr), showing the equation using age, weight, serum creatinine, and a factor for female patients.*

FDA Label Image

Pregabalin 75mg Cap Qty 60 80425 0029

Label for Pregabalin 75 mg capsules, package of 60, by Advanced Rx of Tennessee, LLC. Includes NDC 80425-0029-01, lot number, and storage instructions to keep between 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). The label notes it is comparable to LYRICA and includes a caution about federal law restricting transfer of the drug.*

FDA Label Image

Pregabalin 75mg Cap Qty 90 80425 0029

Label for Pregabalin 75 mg oral capsules manufactured by Advanced Rx of Tennessee, LLC. The label includes the proprietary name Pregabalin, National Drug Code (NDC) 80425-0029-02, lot number 90PR75822, and expiration date 8/31/2022. Storage instructions note to keep at room temperature 20°–25°C (68°–77°F). The label also contains a federal caution against unauthorized transfer of the drug.*

FDA Label Image

Structure

Chemical structure of Pregabalin, showing its molecular backbone with amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.